Dyslipidaemia Clinical Trial
Official title:
A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia
AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate the dose-dependent reduction in LDL-C after SC administration of multiple doses of AZD8233 as well as the associated adverse effects profile. The data generated will be used to guide choice of doses, dosing regimens, and sample sizes, as well as safety and PD monitoring in the further clinical development program.
This is a randomized parallel, double-blind, placebo-controlled, dose-ranging Phase 2b study in approximately 108 participants with dyslipidemia. The primary objective of the study is to investigate the effect of AZD8233 on LDL-C across different dose levels. The study will be conducted at up to 25 sites in up to 4 countries. The screening period starts up to 42 days before the randomization visit and ends on Day -1. Eligible participants will attend 7 visits during the treatment period and 7 additional visits during the safety follow up period. Eligible participants are randomized across four different treatment arms in a 1:1:1:1 ratio for a 12-week treatment period. The planned treatment arms are AZD8233 low dose, AZD8233 medium dose, AZD8233 high dose, and Placebo. Participants will be dosed SC on Days 1, 8, 29, and 57. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02230241 -
CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II)
|
N/A | |
| Completed |
NCT01451918 -
Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol
|
Phase 2 | |
| Recruiting |
NCT01212328 -
A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strategies to Reduce Cardiovascular Disease (CVD) Risk Among 1,120 Type 2 Diabetes Mellitus(T2DM) Patients in South Asia
|
N/A | |
| Completed |
NCT01221584 -
Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia
|
N/A | |
| Completed |
NCT00654225 -
Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)
|
Phase 3 | |
| Withdrawn |
NCT02557412 -
Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea
|
N/A | |
| Completed |
NCT00653965 -
Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)
|
Phase 3 | |
| Recruiting |
NCT04442334 -
The European NAFLD Registry
|
||
| Completed |
NCT00653744 -
Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)
|
Phase 3 | |
| Completed |
NCT01632358 -
Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients
|
Phase 1 | |
| Completed |
NCT02523391 -
Bioequivalence Study of Capsule and Tablet Formulations of TA-8995
|
Phase 1 | |
| Completed |
NCT00474864 -
Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.
|
Phase 2 | |
| Completed |
NCT00659321 -
Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome
|
Phase 3 | |
| Completed |
NCT01055977 -
Statin Therapy Results in the Real World Practice in the Czech Republic
|
N/A | |
| Completed |
NCT00654602 -
48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
|
Phase 3 | |
| Recruiting |
NCT05979428 -
A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood
|
Phase 1 | |
| Completed |
NCT02241759 -
Study of the Electrocardiographic Effects of TA-8995
|
Phase 1 | |
| Completed |
NCT00158899 -
GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
|
Phase 2 |